Biblio
Export 1012 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is C [Clear All Filters]
“Evaluation of the Accuracy of Cognitive Screening Tests in Detecting Dementia Associated with Alzheimer's Disease: A Hierarchical Bayesian Latent Class Meta-Analysis.”, J Alzheimers Dis, vol. 87, no. 1, pp. 285-304, 2022.
, “Evaluation of the Accuracy of Cognitive Screening Tests in Detecting Dementia Associated with Alzheimer's Disease: A Hierarchical Bayesian Latent Class Meta-Analysis.”, J Alzheimers Dis, vol. 87, no. 1, pp. 285-304, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Informal Caregivers' Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 971-984, 2022.
, “Informal Caregivers' Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study.”, J Alzheimers Dis, vol. 88, no. 3, pp. 971-984, 2022.
, “Investigating Causal Relations Between Circulating Metabolites and Alzheimer's Disease: A Mendelian Randomization Study.”, J Alzheimers Dis, vol. 87, no. 1, pp. 463-477, 2022.
, “Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project.”, J Alzheimers Dis, vol. 87, no. 1, pp. 173-183, 2022.
, “Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project.”, J Alzheimers Dis, vol. 87, no. 1, pp. 173-183, 2022.
, “Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project.”, J Alzheimers Dis, vol. 87, no. 1, pp. 173-183, 2022.
, “Peptidylarginine Deiminase and Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 473-484, 2022.
, “Peptidylarginine Deiminase and Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 473-484, 2022.
, “Post-Stroke Cognitive Impairment: Epidemiology, Risk Factors, and Management.”, J Alzheimers Dis, vol. 86, no. 3, pp. 983-999, 2022.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Relationship Between the Gut Microbiota and Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 87, no. 2, pp. 519-528, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
, “Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.”, J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
, “Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1121-1132, 2023.
,